Saturday, October 26, 2013

Iron metabolism and the role of iron in neurodegenerative disorders

Iron metabolism and the role of iron in neurodegenerative disorders; Maya Hadzhieva, Elmar Kirches, Christian Mawrin. Neuropathology and Applied Neurobiology
Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.) DOI: 10.1111/nan.12096

KEYWORDS: neurodegeneration; ROS; iron; mitoferrin; TfR; DMT1; ferritin; frataxin; IscU

Late onset Friedreich ataxia: clinical description of a family in Argentina.

Late onset Friedreich ataxia: clinical description of a family in Argentina.; Perez Akly M and Alvarez F Medicina (B Aires). 2013;73(5):457-460.

FULL TEXT PDF (Spanish)

Unclassified cardiomyopathies in neuromuscular disorders.

Unclassified cardiomyopathies in neuromuscular disorders.. Finsterer J, Stöllberger; Wien Med Wochenschr 2013 Oct 24

Clinical Neurogenetics : Friedreich Ataxia

Clinical Neurogenetics : Friedreich Ataxia. Abigail Collins; Neurologic Clinics, Volume 31, Issue 4, November 2013, Pages 1095-1120. http://dx.doi.org/10.1016/j.ncl.2013.05.002

Thursday, October 24, 2013

Modelling biochemical features of mitochondrial neuropathology

Modelling biochemical features of mitochondrial neuropathology ; Matthew J. Bird, David R. Thorburn, Ann E. Frazier; Biochimica et Biophysica Acta (BBA) - General Subjects, Available online 23 October 2013. http://dx.doi.org/10.1016/j.bbagen.2013.10.017

Keywords: Neuropathology; mitochondrial disease; mouse models; cybrids; iPS; OXPHOS; membrane potential; Ca2 +; reactive oxygen species; mitochondrial morphology; frataxin

Tuesday, October 22, 2013

The Nervous System Cytoskeleton under Oxidative Stress

The Nervous System Cytoskeleton under Oxidative Stress. Gardiner, J.; Overall, R.; Marc, J.; Diseases 2013, 1, 36-50.

FULL TEXT PDF

Monday, October 21, 2013

Fixing Frataxin: “Ironing Out” the Metabolic Defect in Friedreich's Ataxia

Fixing Frataxin: “Ironing Out” the Metabolic Defect in Friedreich's Ataxia. A. Anzovino, D. J. R. Lane, M. L.-H. Huang, D. R. Richardson, British Journal of Pharmacology, Accepted manuscript online: 21 OCT 2013, DOI: 10.1111/bph.12470

Keywords: Frataxin; Mitochondrial Iron Accumulation; Oxidative Stress; Autophagy; Cardio- and Neuro-Degeneration; Friedriech's Ataxia

Saturday, October 19, 2013

Open-label Pilot Study of Interferon Gamma-1b (Actimmune™) for the Treatment of Friedreich Ataxia

Open-label Pilot Study of Interferon Gamma-1b (Actimmune™) for the Treatment of Friedreich Ataxia. ClinicalTrials.gov (October 17, 2013).

Friedreich ataxia (FRDA) is a progressive neurodegenerative disease of children and adults for which there is presently no therapy. Recently, a study reported that interferon gamma (IFN-g) could raise frataxin protein levels in both cell lines derived from patients with Friedreich ataxia and in a mouse model with Friedreich ataxia. The present study will test whether IFN-g is safe, tolerated and potentially efficacious in a heterogeneous cohort of children with FRDA.

Sponsor: Children's Hospital of Philadelphia
Collaborators: Friedreich Ataxia Research Alliance (FARA), Vidara Therapeutics Research Ltd
Information provided by (Responsible Party): Children's Hospital of Philadelphia

Friday, October 18, 2013

Developing epigenetic diagnostics and therapeutics for brain disorders

Developing epigenetic diagnostics and therapeutics for brain disorders. Irfan A. Qureshi, Mark F. Mehler; Trends in Molecular Medicine, Available online 18 October 2013. http://dx.doi.org/10.1016/j.molmed.2013.09.003

Keywords: bromodomain; epigenomic; exosome; glioma; histone deacetylase; long non-coding RNA; microRNA

Thursday, October 17, 2013

EPI-743 in Friedreich's Ataxia Point Mutations

EPI-743 in Friedreich's Ataxia Point Mutations.

The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's Ataxia point mutations.

Official Title: A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations.

Sponsor: University of South Florida
Collaborators: Edison Pharmaceuticals Inc, Friedreich's Ataxia Research Alliance